Furthermore, in resistant patients, CD8+ T-cells mean abundance was higher in cluster1 resistant patient tumor samples than that of cluster2 resistant patients (14.5% vs 7.6%, P = 0.013; Fig. 4j, Supp. This evidence concerns the gene CD8A and neoplasm.